Donegan W L, Padrta B
Department of Surgery, Medical College of Wisconsin, Milwaukee.
Arch Surg. 1990 May;125(5):578-82. doi: 10.1001/archsurg.1990.01410170024004.
The prognosis for patients with inflammatory breast cancer has improved in recent years. This review was undertaken to evaluate current management in three Milwaukee (Wis) hospitals and to identify determinants of prognosis. We identified 25 patients with inflammatory breast carcinoma diagnosed between 1967 and 1987. Most of the patients were treated with combination chemotherapy and radiation therapy, and 10 had mastectomies. The 5-year survival of patients without initial distant metastases was 24%. The 5-year survival of patients who received chemotherapy before local treatment was 40%. Patients who had clinically involved axillary nodes or a palpable mass in the breast had poorer survival than those who did not; the presence of dermal lymphatic invasion had no significant effect on survival. Initial chemotherapy has become an important part of the care of patients with inflammatory breast cancer. It remains uncertain whether mastectomy improves on irradiation in achieving local control or improves survival.
近年来，炎性乳腺癌患者的预后有所改善。本综述旨在评估威斯康星州密尔沃基市三家医院的当前治疗方法，并确定预后的决定因素。我们确定了1967年至1987年间诊断出的25例炎性乳腺癌患者。大多数患者接受了联合化疗和放疗，10例患者接受了乳房切除术。无初始远处转移患者的5年生存率为24%。在局部治疗前接受化疗的患者5年生存率为40%。有临床腋窝淋巴结受累或乳房可触及肿块的患者生存率低于无此类情况的患者；真皮淋巴管侵犯的存在对生存率无显著影响。初始化疗已成为炎性乳腺癌患者治疗的重要组成部分。乳房切除术在实现局部控制或提高生存率方面是否优于放疗仍不确定。
